moxifloxacin-acetic acid conjugate

Moxifloxacin-acetic acid conjugate (also known as compound 14m) is a novel amide derivative synthesized by conjugating the fluoroquinolone antibiotic moxifloxacin with acetic acid. This conjugate was developed as part of a series of fatty acid-moxifloxacin hybrids designed to enhance antibacterial potency and cytotoxic activity. In preclinical evaluations, 14m emerged as a lead structure, demonstrating significant antibacterial activity against standard isolates and clinical coagulase-negative staphylococci, with a minimum inhibitory concentration (MIC) of 0.5 μg/mL for quinolone-susceptible strains. Its mechanism of action involves the dual inhibition of bacterial DNA gyrase and topoisomerase IV, effectively interfering with DNA supercoiling and decatenation. Additionally, while other conjugates in the series showed high cytotoxic potential against prostate cancer cells, 14m is primarily noted for its optimized antibacterial profile.

Other names

moxifloxacin acetic acid amidecompound 14mcompound14mcompound-14m